New pill for eczema and psoriasis enters human safety testing

NCT ID NCT06982352

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This early-stage study tests a new oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. The main goal is to check if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through the body. This is not a cure; it aims to control these chronic skin conditions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Investigations of Texas

    RECRUITING

    Dallas, Texas, 75075, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Red River Research Partners

    RECRUITING

    Fargo, North Dakota, 58103, United States

  • Triumpharma Clinical Research Unit at AlEssra Hospital

    RECRUITING

    Amman, Jordan, B204, Jordan

Conditions

Explore the condition pages connected to this study.